Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Hena Khalique

MSc, PhD

Postdoctoral Researcher

Oncolytic HSV-1-mediated virotherapy, T cell immunotherapy, Cancer Biology

Research Summary

In my research I am trying to turn the cold suppressive environment of tumour to hot by activating tumour resident T cells. For this, I have constructed a Bi-specific T cells engager (BiTE) which recognizes target cells and T cells and crosslinks them in a ‘pseudo-synapse’. Binding of multiple BiTEs activates T cells and kills target cells.

I am planning to use these agents in combination with oncolytic Herpes Simplex Virus-1 (oHSV-1) to trigger diverse innate immune pathways. This strategy will provide cancer selectivity and prevent ‘on-target off-tumour’ toxicities.


Hena post-graduated in Biochemistry at the Hamdard University, India which she followed with work at National Brain Research Centre, India. Her research was focused on growth factors mediated protection of human neurons against HIV/AIDS-drug abuse cases. She completed her PhD at Universidad Autonoma de Madrid, Spain. Her thesis was focused on the HSV-1 lytic-latent transition by testing artificial control over ICP0 transcription. In 2017, Hena joined Prof. Leonard Seymour’s group as a postdoctoral researcher in Department of Oncology, University of Oxford.


Recent publications

More publications